Cargando…
Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
Objective: The utility of topotecan monotherapy for relapsed small-cell lung cancer (SCLC) after failure of amrubicin monotherapy has not been evaluated. We aimed to investigate the efficacy and safety of topotecan monotherapy in patients with relapsed SCLC after amrubicin monotherapy. Patients and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Association of Rural Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527629/ https://www.ncbi.nlm.nih.gov/pubmed/34707735 http://dx.doi.org/10.2185/jrm.2021-014 |
_version_ | 1784586106599112704 |
---|---|
author | Fujita, Kohei Nakao, Makoto Arakawa, Sosuke Sone, Kazuki Sato, Hidefumi Muramatsu, Hideki |
author_facet | Fujita, Kohei Nakao, Makoto Arakawa, Sosuke Sone, Kazuki Sato, Hidefumi Muramatsu, Hideki |
author_sort | Fujita, Kohei |
collection | PubMed |
description | Objective: The utility of topotecan monotherapy for relapsed small-cell lung cancer (SCLC) after failure of amrubicin monotherapy has not been evaluated. We aimed to investigate the efficacy and safety of topotecan monotherapy in patients with relapsed SCLC after amrubicin monotherapy. Patients and Methods: We retrospectively analyzed data from 16 patients with relapsed SCLC who were treated with topotecan monotherapy after amrubicin monotherapy at our hospital. Results: The response rate, progression-free survival, and overall survival were 0%, 32.5 days (95% confidence interval [CI] = 18–51), and 112 days (95% CI = 55–267), respectively. The most common adverse events (grade ≥3) were leukopenia (31.3%) and thrombocytopenia (31.3%), followed by anemia, anorexia, edema, and lung infections. Conclusion: The efficacy of topotecan monotherapy for relapsed SCLC after amrubicin monotherapy is inconclusive. Therefore, further studies are warranted. |
format | Online Article Text |
id | pubmed-8527629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Japanese Association of Rural Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-85276292021-10-26 Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure Fujita, Kohei Nakao, Makoto Arakawa, Sosuke Sone, Kazuki Sato, Hidefumi Muramatsu, Hideki J Rural Med Original Article Objective: The utility of topotecan monotherapy for relapsed small-cell lung cancer (SCLC) after failure of amrubicin monotherapy has not been evaluated. We aimed to investigate the efficacy and safety of topotecan monotherapy in patients with relapsed SCLC after amrubicin monotherapy. Patients and Methods: We retrospectively analyzed data from 16 patients with relapsed SCLC who were treated with topotecan monotherapy after amrubicin monotherapy at our hospital. Results: The response rate, progression-free survival, and overall survival were 0%, 32.5 days (95% confidence interval [CI] = 18–51), and 112 days (95% CI = 55–267), respectively. The most common adverse events (grade ≥3) were leukopenia (31.3%) and thrombocytopenia (31.3%), followed by anemia, anorexia, edema, and lung infections. Conclusion: The efficacy of topotecan monotherapy for relapsed SCLC after amrubicin monotherapy is inconclusive. Therefore, further studies are warranted. The Japanese Association of Rural Medicine 2021-10-01 2021-10 /pmc/articles/PMC8527629/ /pubmed/34707735 http://dx.doi.org/10.2185/jrm.2021-014 Text en ©2021 The Japanese Association of Rural Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Original Article Fujita, Kohei Nakao, Makoto Arakawa, Sosuke Sone, Kazuki Sato, Hidefumi Muramatsu, Hideki Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure |
title | Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after
amrubicin monotherapy failure |
title_full | Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after
amrubicin monotherapy failure |
title_fullStr | Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after
amrubicin monotherapy failure |
title_full_unstemmed | Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after
amrubicin monotherapy failure |
title_short | Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after
amrubicin monotherapy failure |
title_sort | evaluation of topotecan monotherapy for relapsed small-cell lung cancer after
amrubicin monotherapy failure |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527629/ https://www.ncbi.nlm.nih.gov/pubmed/34707735 http://dx.doi.org/10.2185/jrm.2021-014 |
work_keys_str_mv | AT fujitakohei evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure AT nakaomakoto evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure AT arakawasosuke evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure AT sonekazuki evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure AT satohidefumi evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure AT muramatsuhideki evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure |